HRP20200805T1 - Spirociklički spojevi - Google Patents
Spirociklički spojevi Download PDFInfo
- Publication number
- HRP20200805T1 HRP20200805T1 HRP20200805TT HRP20200805T HRP20200805T1 HR P20200805 T1 HRP20200805 T1 HR P20200805T1 HR P20200805T T HRP20200805T T HR P20200805TT HR P20200805 T HRP20200805 T HR P20200805T HR P20200805 T1 HRP20200805 T1 HR P20200805T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- alkyl
- group
- hydrogen
- cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 125000003107 substituted aryl group Chemical group 0.000 claims 35
- 229910052739 hydrogen Inorganic materials 0.000 claims 34
- 239000001257 hydrogen Substances 0.000 claims 34
- 125000001072 heteroaryl group Chemical group 0.000 claims 31
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 31
- 210000004027 cell Anatomy 0.000 claims 26
- 125000000623 heterocyclic group Chemical group 0.000 claims 25
- 150000002431 hydrogen Chemical group 0.000 claims 25
- 125000003277 amino group Chemical group 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 125000000547 substituted alkyl group Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 10
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims 7
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 6
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 4
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 claims 3
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 208000009905 Neurofibromatoses Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000025113 myeloid leukemia Diseases 0.000 claims 3
- 201000004931 neurofibromatosis Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 235000013877 carbamide Nutrition 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- -1 monosubstituted amino Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 150000003672 ureas Chemical class 0.000 claims 2
- OBKRRKAUHSPXPC-QNGWXLTQSA-N (5S)-2-[3-(1-acetylpiperidin-4-yl)-2H-indazol-5-yl]-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-2,7-diazaspiro[4.4]nonan-1-one Chemical compound CN1C=NC(=N1)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3CCN(CC3)C(C)=O)C=C2)C1 OBKRRKAUHSPXPC-QNGWXLTQSA-N 0.000 claims 1
- GTZJXZZYRIMYEL-LHEWISCISA-N (5S)-2-[3-(2-methyl-1,3-benzoxazol-5-yl)-1H-indazol-5-yl]-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-2,7-diazaspiro[4.4]nonan-1-one Chemical compound CN1N=C(N=C1)C1=CC=C(C=C1)C=1CCN(CC=1)C(CN1C[C@@]2(CCN(C2=O)C=2C=C3C(=NNC3=CC=2)C=2C=CC3=C(N=C(O3)C)C=2)CC1)=O GTZJXZZYRIMYEL-LHEWISCISA-N 0.000 claims 1
- NWPDFALVYJWUJA-DHUJRADRSA-N (5S)-2-[3-(3,6-dihydro-2H-pyran-4-yl)-1H-indazol-5-yl]-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-2,7-diazaspiro[4.4]nonan-1-one Chemical compound CN1C=NC(=N1)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3=CCOCC3)C=C2)C1 NWPDFALVYJWUJA-DHUJRADRSA-N 0.000 claims 1
- RSOAEEGYFGFBCE-QNGWXLTQSA-N (5S)-2-[3-(4-methoxyphenyl)-1H-indazol-5-yl]-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-2,7-diazaspiro[4.4]nonan-1-one Chemical compound COC1=CC=C(C=C1)C1=NNC2=C1C=C(C=C2)N1CC[C@]2(CCN(CC(=O)N3CCC(=CC3)C3=CC=C(C=C3)C3=NN(C)C=N3)C2)C1=O RSOAEEGYFGFBCE-QNGWXLTQSA-N 0.000 claims 1
- KJEOBKKNJGKUMR-BHVANESWSA-N (5S)-2-[3-(4-methoxypiperidin-1-yl)-1H-indazol-5-yl]-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-2,7-diazaspiro[4.4]nonan-1-one Chemical compound COC1CCN(CC1)C1=NNC2=C1C=C(C=C2)N1CC[C@]2(CCN(CC(=O)N3CCC(=CC3)C3=CC=C(C=C3)C3=NN(C)C=N3)C2)C1=O KJEOBKKNJGKUMR-BHVANESWSA-N 0.000 claims 1
- BPGVSQWUBDBBAJ-DHUJRADRSA-N (5S)-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-2-[3-(oxan-4-yl)-2H-indazol-5-yl]-2,7-diazaspiro[4.4]nonan-1-one Chemical compound CN1C=NC(=N1)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3CCOCC3)C=C2)C1 BPGVSQWUBDBBAJ-DHUJRADRSA-N 0.000 claims 1
- AQZWQCDSFJRAEJ-DHUJRADRSA-N (5S)-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-2-[3-[6-(trifluoromethyl)pyridin-3-yl]-1H-indazol-5-yl]-2,7-diazaspiro[4.4]nonan-1-one Chemical compound CN1C=NC(=N1)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3=CC=C(N=C3)C(F)(F)F)C=C2)C1 AQZWQCDSFJRAEJ-DHUJRADRSA-N 0.000 claims 1
- XHFIEJBGBYWSDA-DHUJRADRSA-N (5S)-7-[2-[4-[5-(1-methyl-1,2,4-triazol-3-yl)-1,3-thiazol-2-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-2-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]-2,7-diazaspiro[4.4]nonan-1-one Chemical compound CC(C)OC1=CC=C(C=N1)C1=NNC2=C1C=C(C=C2)N1CC[C@]2(CCN(CC(=O)N3CCC(=CC3)C3=NC=C(S3)C3=NN(C)C=N3)C2)C1=O XHFIEJBGBYWSDA-DHUJRADRSA-N 0.000 claims 1
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 1
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 claims 1
- GAXAFTQHTHBBPG-LHEWISCISA-N 2-methoxy-4-[5-[(5S)-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl]-1H-indazol-3-yl]benzonitrile Chemical compound COC1=C(C=CC(=C1)C1=NNC2=C1C=C(C=C2)N1CC[C@]2(CCN(CC(=O)N3CCC(=CC3)C3=CC=C(C=C3)C3=NN(C)C=N3)C2)C1=O)C#N GAXAFTQHTHBBPG-LHEWISCISA-N 0.000 claims 1
- QUTCNADPXCXUDU-LHEWISCISA-N 2-methoxy-5-[5-[(5S)-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl]-1H-indazol-3-yl]benzonitrile Chemical compound COC1=C(C=C(C=C1)C1=NNC2=C1C=C(C=C2)N1CC[C@]2(CCN(CC(=O)N3CCC(=CC3)C3=CC=C(C=C3)C3=NN(C)C=N3)C2)C1=O)C#N QUTCNADPXCXUDU-LHEWISCISA-N 0.000 claims 1
- BIGWXAGEQONZGD-UHFFFAOYSA-N 2h-oxadiazol-5-one Chemical class O=C1C=NNO1 BIGWXAGEQONZGD-UHFFFAOYSA-N 0.000 claims 1
- AVPCTOPEWYDAOF-QNGWXLTQSA-N 3-[5-[(5S)-7-[2-[4-[4-(4-methyl-5-oxo-1,3,4-oxadiazol-2-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl]-1H-indazol-3-yl]benzonitrile Chemical compound CN1N=C(OC1=O)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3=CC=CC(=C3)C#N)C=C2)C1 AVPCTOPEWYDAOF-QNGWXLTQSA-N 0.000 claims 1
- UBIWVURAOAWIKD-LHEWISCISA-N 3-methyl-5-[4-[1-[2-[(5S)-1-oxo-2-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]-2,7-diazaspiro[4.4]nonan-7-yl]acetyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]-1,3,4-oxadiazol-2-one Chemical compound CC(C)OC1=CC=C(C=N1)C1=NNC2=C1C=C(C=C2)N1CC[C@]2(CCN(CC(=O)N3CCC(=CC3)C3=CC=C(C=C3)C3=NN(C)C(=O)O3)C2)C1=O UBIWVURAOAWIKD-LHEWISCISA-N 0.000 claims 1
- YTBBIYPNNDERSK-UMSFTDKQSA-N 3-methyl-5-[4-[1-[2-[(5S)-2-(3-morpholin-4-yl-1H-indazol-5-yl)-1-oxo-2,7-diazaspiro[4.4]nonan-7-yl]acetyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]-1,3,4-oxadiazol-2-one Chemical compound CN1N=C(OC1=O)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3N3CCOCC3)C=C2)C1 YTBBIYPNNDERSK-UMSFTDKQSA-N 0.000 claims 1
- VOQRHOCHBNQSDK-DHUJRADRSA-N 3-methyl-5-[4-[1-[2-[(5S)-2-[3-(oxan-4-yl)-2H-indazol-5-yl]-1-oxo-2,7-diazaspiro[4.4]nonan-7-yl]acetyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]-1,3,4-oxadiazol-2-one Chemical compound CN1N=C(OC1=O)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3CCOCC3)C=C2)C1 VOQRHOCHBNQSDK-DHUJRADRSA-N 0.000 claims 1
- WTSXVIMLKCKWIW-UHFFFAOYSA-N 3h-1,3,4-oxadiazol-2-one Chemical class O=C1NN=CO1 WTSXVIMLKCKWIW-UHFFFAOYSA-N 0.000 claims 1
- AZRIIERYKDENHS-QNGWXLTQSA-N 4-[5-[(5S)-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl]-1H-indazol-3-yl]benzonitrile Chemical compound CN1C=NC(=N1)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3=CC=C(C=C3)C#N)C=C2)C1 AZRIIERYKDENHS-QNGWXLTQSA-N 0.000 claims 1
- CFIIXPSJXDHGHV-QNGWXLTQSA-N 4-[5-[(5S)-7-[2-[4-[4-(4-methyl-5-oxo-1,3,4-oxadiazol-2-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl]-1H-indazol-3-yl]benzonitrile Chemical compound CN1N=C(OC1=O)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3=CC=C(C=C3)C#N)C=C2)C1 CFIIXPSJXDHGHV-QNGWXLTQSA-N 0.000 claims 1
- PGOSFFMPLHMFDQ-QNGWXLTQSA-N 5-[4-[1-[2-[(5S)-2-[3-(1-acetylpiperidin-4-yl)-2H-indazol-5-yl]-1-oxo-2,7-diazaspiro[4.4]nonan-7-yl]acetyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]-3-methyl-1,3,4-oxadiazol-2-one Chemical compound CN1N=C(OC1=O)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3CCN(CC3)C(C)=O)C=C2)C1 PGOSFFMPLHMFDQ-QNGWXLTQSA-N 0.000 claims 1
- JQOOTZJBZLSXKF-BHVANESWSA-N 5-[4-[1-[2-[(5S)-2-[3-(4-methoxypiperidin-1-yl)-1H-indazol-5-yl]-1-oxo-2,7-diazaspiro[4.4]nonan-7-yl]acetyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]-3-methyl-1,3,4-oxadiazol-2-one Chemical compound COC1CCN(CC1)C1=NNC2=C1C=C(C=C2)N1CC[C@]2(CCN(CC(=O)N3CCC(=CC3)C3=CC=C(C=C3)C3=NN(C)C(=O)O3)C2)C1=O JQOOTZJBZLSXKF-BHVANESWSA-N 0.000 claims 1
- AMSLGMCDVAAHDF-QNGWXLTQSA-N 5-[5-[(5S)-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl]-1H-indazol-3-yl]-2-(trifluoromethoxy)benzonitrile Chemical compound CN1C=NC(=N1)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3=CC(C#N)=C(OC(F)(F)F)C=C3)C=C2)C1 AMSLGMCDVAAHDF-QNGWXLTQSA-N 0.000 claims 1
- UDDFHCJAKAMSMK-QNGWXLTQSA-N 5-[5-[(5S)-7-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl]-1H-indazol-3-yl]-2-(trifluoromethyl)benzonitrile Chemical compound CN1C=NC(=N1)C1=CC=C(C=C1)C1=CCN(CC1)C(=O)CN1CC[C@]2(CCN(C2=O)C2=CC3=C(NN=C3C3=CC(C#N)=C(C=C3)C(F)(F)F)C=C2)C1 UDDFHCJAKAMSMK-QNGWXLTQSA-N 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 150000002429 hydrazines Chemical class 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002545 isoxazoles Chemical class 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 150000002916 oxazoles Chemical class 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Claims (15)
1. Spoj Formule (I):
[image]
pri čemu:
R1 se odabire iz skupine koja se sastoji od vodika, opcionalno supstituiranog alkila, opcionalno supstituiranog alkenila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog cikloalkenila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog heterociklila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog cikloalkenil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila), hidroksiskupine, opcionalno supstituirane alkoksiskupine, cijanoskupine, opcionalno supstituirane C-karboksiskupine, opcionalno supstituirane N-amidoskupine, opcionalno supstituirane ureje, nitroskupine, opcionalno supstituiranog sulfenila, opcionalno supstituiranog haloalkila, aminoskupine, opcionalno supstituirane monosupstituirane aminoskupine, opcionalno supstituirane disupstituirane aminoskupine i -(CR1a1R1a2)q-R1b, pri čemu je q 1, 2, 3, 4, 5 ili 6, a svaki R1a1 i svaki R1a2 neovisno su vodik, halogen ili nesupstituirani alkil, a R1b odabire se iz skupine koja se sastoji od hidroksiskupine, opcionalno supstituirane N-amidoskupine, opcionalno supstituirane N-sulfinamidoskupine, opcionalno supstituirane N-sulfonamidoskupine, opcionalno supstituirane ureje, opcionalno supstituiranog sulfenila, aminoskupine, opcionalno supstituirane monosupstituirane aminoskupine i opcionalno supstituirane disupstituirane aminoskupine
Y1, Y2 i Y3 neovisno su C ili N
pod uvjetom da kada je Y1 C, tada se R2a odabire iz skupine koja se sastoji od vodika, halogena, opcionalno supstituiranog alkila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog heterociklila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila), hidroksiskupine, opcionalno supstituirane alkoksiskupine, cijanoskupine, nitroskupine, opcionalno supstituiranog sulfenila, aminoskupine, opcionalno supstituirane monosupstituirane aminoskupine i opcionalno supstituirane disupstituirane aminoskupine, a kada je Y1 N, tada R2a nije prisutan
pod uvjetom da kada je Y2 C, tada se R2b odabire iz skupine koja se sastoji od vodika, halogena, opcionalno supstituiranog alkila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog heterociklila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila), hidroksiskupine, opcionalno supstituirane alkoksiskupine, cijanoskupine, nitroskupine, opcionalno supstituiranog sulfenila, aminoskupine, opcionalno supstituirane monosupstituirane aminoskupine i opcionalno supstituirane disupstituirane aminoskupine, a kada je Y2 N, tada R2b nije prisutan
pod uvjetom da kada je Y3 C, tada se R2c odabire iz skupine koja se sastoji od vodika, halogena, opcionalno supstituiranog alkila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog heterociklila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila), hidroksiskupine, opcionalno supstituirane alkoksiskupine, cijanoskupine, nitroskupine, opcionalno supstituiranog sulfenila, aminoskupine, opcionalno supstituirane monosupstituirane aminoskupine i opcionalno supstituirane disupstituirane aminoskupine, a kada je Y3 N, tada R2c nije prisutan
svaki R3a, svaki R3b, R3c, R3d, svaki R3e, svaki R3f, R3g, R3h, R3i i R3j neovisno se odabiru iz skupine koja se sastoji od vodika, halogena, opcionalno supstituiranog alkila, opcionalno supstituiranog alkenila, opcionalno supstituiranog alkinila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog heterociklila, opcionalno supstituiranog cikloalkila(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila), hidroksiskupine, opcionalno supstituirane alkoksiskupine, opcionalno supstituirane haloalkoksiskupine, cijanoskupine, opcionalno supstituirane N-amidoskupine, opcionalno supstituirane C-karboksiskupine, opcionalno supstituiranog oksima, opcionalno supstituiranog acilhidrazona, opcionalno supstituiranog sulfenila, opcionalno supstituiranog sulfinila, opcionalno supstituiranog sulfonila, aminoskupine, opcionalno supstituirane monosupstituirane aminoskupine, opcionalno supstituirane disupstituirane aminoskupine i skupine -(CH2)r-R3k, pri čemu je r 1, 2, 3, 4, 5 ili 6, a R3k odabire se iz skupine koja se sastoji od haloskupine, hidroksiskupine, cijanoskupine, opcionalno supstituiranog heteroarila, opcionalno supstituirane alkoksiskupine, opcionalno supstituiranog sulfenila i opcionalno supstituiranog hidrazina
svaki R4a i svaki R4b neovisno su vodik, deuterij ili opcionalno supstituiran alkil
R5a, R5b, R5c, R5e, R5f, R5g i R5h neovisno se odabiru iz skupine koja se sastoji od vodika, opcionalno supstituiranog alkila, opcionalno supstituiranog alkenila, opcionalno supstituiranog alkinila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila) i opcionalno supstituirane C-karboksiskupine ili
R5b i R5c zajedno se vežu kako bi se stvorio opcionalno supstituiran cikloalkil, opcionalno supstituiran aril ili opcionalno supstituiran heterociklil, a R5a, R5e, R5f, R5g i R5h neovisno se odabiru iz skupine koja se sastoji od vodika, opcionalno supstituiranog alkila, opcionalno supstituiranog alkenila, opcionalno supstituiranog alkinila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila) i opcionalno supstituirane C-karboksiskupine ili
R5f i R5g zajedno se vežu kako bi se stvorio opcionalno supstituiran cikloalkil, opcionalno supstituiran aril ili opcionalno supstituiran heterociklil, a R5a, R5b, R5c, R5e i R5h neovisno se odabiru iz skupine koja se sastoji od vodika, opcionalno supstituiranog alkila, opcionalno supstituiranog alkenila, opcionalno supstituiranog alkinila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila) i opcionalno supstituirane C-karboksiskupine ili
R5b i R5c zajedno se vežu kako bi se stvorio opcionalno supstituiran cikloalkil, opcionalno supstituiran aril ili opcionalno supstituiran heterociklil, R5f i R5g zajedno se vežu kako bi se stvorio opcionalno supstituiran cikloalkil, opcionalno supstituiran aril ili opcionalno supstituiran heterociklil, a R5a, R5e i R5h neovisno se odabiru iz skupine koja se sastoji od vodika, opcionalno supstituiranog alkila, opcionalno supstituiranog alkenila, opcionalno supstituiranog alkinila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila) i opcionalno supstituirane C-karboksiskupine ili
R5b i R5g povezani su putem Y5, pri čemu je Y5 (CR5iR5j)s, pri čemu je s 1, 2 ili 3, svaki R5i i svaki R5j neovisno su vodik, halogen ili nesupstituirani alkil, a R5a, R5c, R5e, R5f i R5h neovisno se odabiru iz skupine koja se sastoji od vodika, opcionalno supstituiranog alkila, opcionalno supstituiranog alkenila, opcionalno supstituiranog alkinila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila) i opcionalno supstituirane C-karboksiskupine
R5C i R5e povezani su putem Y6, pri čemu je Y6 (CR5kR5l)t, pri čemu je t 1, 2 ili 3, svaki R5j i svaki R51 neovisno su vodik, halogen ili nesupstituirani alkil, a R5a, R5b, R5f, R5g i R5h neovisno se odabiru iz skupine koja se sastoji od vodika, opcionalno supstituiranog alkila, opcionalno supstituiranog alkenila, opcionalno supstituiranog alkinila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila) i opcionalno supstituirane C-karboksiskupine
R6 je opcionalno supstituiran aril, opcionalno supstituiran heteroaril ili opcionalno supstituiran heterociklil
A1 se odabire iz skupine koja se sastoji od opcionalno supstituiranog C3-10 cikloalkila, opcionalno supstituiranog C3-10 cikloalkenila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila i opcionalno supstituiranog heterociklila
X1 je vodik, O ili S, pod uvjetom da kada je X1 vodik, tada je ------ jednostruka veza, a kada je X1 O ili S, tada je ------ dvostruka veza
X2 je O ili S
Y4 je C(Y1a), C ili N
Y1a odabire se iz skupine koja se sastoji od vodika, halogena, nesupstituiranog C1-4 alkila i -O-C1-4 alkila
------ je jednostruka ili dvostruka veza
pri čemu kada je Y4 C(Y1a), a ------ je jednostruka veza, tada se R5d odabire se iz skupine koja se sastoji od vodika, opcionalno supstituiranog alkila, opcionalno supstituiranog alkenila, opcionalno supstituiranog alkinila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila) i opcionalno supstituirane C-karboksiskupine
pri čemu kada je Y4 C, a ------ je dvostruka veza, tada R5d nije prisutan te
pri čemu kada je Y4 N, tada je ------ jednostruka veza, a R5d se odabire iz skupine koja se sastoji od vodika, opcionalno supstituiranog alkila, opcionalno supstituiranog alkenila, opcionalno supstituiranog alkinila, opcionalno supstituiranog cikloalkila, opcionalno supstituiranog arila, opcionalno supstituiranog heteroarila, opcionalno supstituiranog cikloalkil(alkila), opcionalno supstituiranog aril(alkila), opcionalno supstituiranog heteroaril(alkila), opcionalno supstituiranog heterociklil(alkila) i opcionalno supstituirane C-karboksiskupine
m je 0, 1 ili 2
n je 0, 1 ili 2 i
p je 1, 2 ili 3.
2. Spoj u skladu sa zahtjevom 1, pri čemu je m 1 ili 2; n je 0 ili 1; svaki R3a, svaki R3b, R3c, R3d, svaki R3e, svaki R3f, R3g, R3h, R3i i R3j sastoje se svaki od vodika; X1 je vodik; ------- je jednostruka veza te je X2 O ili pri čemu je m 1 ili 2; n je 0 ili 1; svaki R3a, svaki R3b, R3c, R3d, svaki R3e, svaki R3f, R3g, R3h, R3i i R3j sastoje se svaki od vodika; X1 je O; ------- je dvostruka veza, a X2 je O.
3. Spoj u skladu s bilo kojim zahtjevom od 1 do 2, pri čemu je R1 opcionalno supstituiran cikloalkil ili pri čemu je R1 opcionalno supstituiran C4-8 cikloalkil ili pri čemu je R1 opcionalno supstituiran cikloalkenil ili pri čemu je R1 opcionalno supstituiran C6-8 cikloalkenil ili pri čemu je R1 opcionalno supstituiran aril ili pri čemu je R1 opcionalno supstituiran fenil ili pri čemu je R1 opcionalno supstituiran heteroaril ili pri čemu je R1 opcionalno supstituiran monociklički heteroaril ili pri čemu je R1 opcionalno supstituiran biciklički heteroaril ili pri čemu je R1 opcionalno supstituiran heterociklil ili pri čemu je R1 opcionalno supstituiran monociklički heterociklil ili pri čemu je R1 opcionalno supstituiran biciklički heterociklil ili pri čemu je R1 cijanoskupina ili pri čemu je R1 vodik ili pri čemu je R1 opcionalno supstituiran haloalkil ili pri čemu je R1 opcionalno supstituirana monosupstituirana aminoskupina.
4. Spoj u skladu s bilo kojim zahtjevom od 1 do 3, pri čemu je Y1 C; R2a je vodik, halogen ili opcionalno supstituiran C1-4 alkil; Y2 je C; R2b je vodik, halogen ili opcionalno supstituiran C1-4 alkil; Y3 je C, a R2c je vodik, halogen ili opcionalno supstituiran C1-4 alkil; ili pri čemu je Y1 N; R2a nije prisutan; Y2 je C; R2b je vodik, halogen ili opcionalno supstituiran C1-4 alkil; Y3 je C, a R2c je vodik, halogen ili opcionalno supstituiran C1-4 alkil.
5. Spoj u skladu s bilo kojim zahtjevom od 1 do 4, pri čemu je p 1, a svaki R4a i svaki R4b sastoje se od vodika.
6. Spoj u skladu s bilo kojim zahtjevom od 1 do 5, pri čemu je Y4 C(Y1a) i ------ je jednostruka veza, a R5a, R5b, R5c, R5d, R5e, R5f, R5g i R5h sastoje se svaki od vodika ili pri čemu je Y4 CH ili CF i ------ je jednostruka veza, a R5a, R5b, R5c, R5d, R5e, R5f, R5g i R5h sastoje se svaki od vodika ili pri čemu je Y4 C, ------ je dvostruka veza, R5d nije prisutan, a R5a, R5b, R5c, R5e, R5f, R5g i R5h sastoje se svaki od vodika ili pri čemu je Y4 N, ------ je jednostruka veza, a R5a, R5b, R5c, R5d, R5e, R5f, R5g i R5h sastoje se svaki od vodika.
7. Spoj u skladu s bilo kojim zahtjevom od 1 do 6, pri čemu je A1 opcionalno supstituiran C3-10 cikloalkil ili pri čemu je A1 opcionalno supstituiran monociklički C5-10 cikloalkil ili pri čemu je A1 opcionalno supstituiran biciklički C3-10 cikloalkil ili pri čemu je A1 opcionalno supstituiran aril ili pri čemu je A1 opcionalno supstituiran fenil.
8. Spoj u skladu s bilo kojim zahtjevom od 1 do 7, pri čemu je R6 opcionalno supstituiran aril ili pri čemu je R6 opcionalno supstituiran fenil ili pri čemu je R6 opcionalno supstituiran heteroaril ili pri čemu je R6 opcionalno supstituiran monociklički heteroaril ili pri čemu je R6 opcionalno supstituiran biciklički heteroaril; ili pri čemu je R6 opcionalno supstituiran piridin, opcionalno supstituiran pirimidin, opcionalno supstituiran triazol, opcionalno supstituiran izoksazol, opcionalno supstituiran oksazol, opcionalno supstituiran imidazol ili opcionalno supstituiran pirazol ili pri čemu je R6 opcionalno supstituiran 1,3,4-oksadiazol-2(3H)-on ili opcionalno supstituiran 1,2,3-oksadiazol-5(2H)-on.
9. Spoj u skladu sa zahtjevom 1, odabran iz skupine koja se sastoji od sljedećeg:
[image]
[image]
[image]
[image]
[image]
ili farmaceutski prihvatljive soli bilo čega od navedenog
ili pri čemu se spoj odabire iz skupine koja se sastoji od sljedećeg:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
(S)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2-(3-(2-metilbenzo[d]oksazol-5-il)-1H-indazol-5-il)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-7-(2-(4-(4-(1-ciklopropil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2-(3-(6-izopropoksipiridin-3-il)-1H-pirazolo[4,3-b]piridin-5-il)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2-(3-(6-(trifluorometil)piridin-3-il)-1H-indazol-5-il)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-2-(3-(6-(difluorometil)piridin-3-il)-1H-indazol-5-il)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-2-(3-(2-(difluorometil)pirimidin-5-il)-1H-indazol-5-il)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2,7-diazaspiro[4.4]nonan-1-ona
(5S)-2-(3-(6-(1-hidroksipropan-2-il)piridin-3-il)-1H-indazol-5-il)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-2-(3-(6-izopropoksipiridin-3-il)-1H-indazol-5-il)-7-(2-(4-(5-(1-metil-1H-1,2,4-triazol-3-il)tiazol-2-il)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2-(3-(tetrahidro-2H-piran-4-il)-1H-indazol-5-il)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-2-(3-(3,6-dihidro-2H-piran-4-il)-1H-indazol-5-il)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-2-(3-(4-metoksifenil)-1H-indazol-5-il)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-4-(5-(7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-1-okso-2,7-diazaspiro[4.4]nonan-2-il)-1H-indazol-3-il)benzonitrila
(S)-2-metoksi-4-(5-(7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-1-okso-2,7-diazaspiro[4.4]nonan-2-il)-1H-indazol-3-il)benzonitrila
(S)-2-metoksi-5-(5-(7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-1-okso-2,7-diazaspiro[4.4]nonan-2-il)-1H-indazol-3-il)benzonitrila
(S)-2-(3-(1-acetilpiperidin-4-il)-1H-indazol-5-il)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-2-(3-(1-(2-hidroksiacetil)piperidin-4-il)-1H-indazol-5-il)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-5-(5-(7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-1-okso-2,7-diazaspiro[4.4]nonan-2-il)-1H-indazol-3-il)-2-(trifluorometoksi)benzonitrila
(S)-5-(5-(7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-1-okso-2,7-diazaspiro[4.4]nonan-2-il)-1H-indazol-3-il)-2-(trifluorometil)benzonitrila
(S)-2-(3-(4-metoksipiperidin-1-il)-1H-indazol-5-il)-7-(2-(4-(4-(1-metil-1H-1,2,4-triazol-3-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-2,7-diazaspiro[4.4]nonan-1-ona
(S)-5-(4-(1-(2-(7-(3-(6-izopropoksipiridin-3-il)-1H-indazol-5-il)-6-okso-2,7-diazaspiro[4.4]nonan-2-il)acetil)-1,2,3,6-tetrahidropiridin-4-il)fenil)-3-metil-1,3,4-oksadiazol- 2(3H)-ona
(S)-4-(5-(7-(2-(4-(4-(4-metil-5-okso-4,5-dihidro-1,3,4-oksadiazol-2-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-1-okso-2,7-diazaspiro[4.4]nonan-2-il)-1H-indazol-3-il)benzonitrila
(S)-3-(5-(7-(2-(4-(4-(4-metil-5-okso-4,5-dihidro-1,3,4-oksadiazol-2-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-1-okso-2,7-diazaspiro[4.4]nonan-2-il)-1H-indazol-3-il)benzonitrila
(S)-2-metoksi-4-(5-(7-(2-(4-(4-(4-metil-5-okso-4,5-dihidro-1,3,4-oksadiazol-2-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-1-okso-2,7-diazaspiro[4.4]nonan-2-il)-1H-indazol-3-il)benzonitrila
(S)-2-metoksi-5-(5-(7-(2-(4-(4-(4-metil-5-okso-4,5-dihidro-1,3,4-oksadiazol-2-il)fenil)-3,6-dihidropiridin-1(2H)-il)-2-oksoetil)-1-okso-2,7-diazaspiro[4.4]nonan-2-il)-1H-indazol-3-il)benzonitrila
(S)-3-metil-5-(4-(1-(2-(7-(3-(2-metilbenzo[d]oksazol-5-il)-1H-indazol-5-il)-6-okso-2,7-diazaspiro[4.4]nonan-2-il)acetil)-1,2,3,6-tetrahidropiridin-4-il)fenil)-1,3,4-oksadiazol-2(3H)-ona
(S)-3-metil-5-(4-(1-(2-(7-(3-morfolino-1H-indazol-5-il)-6-okso-2,7-diazaspiro[4.4]nonan-2-il)acetil)-1,2,3,6-tetrahidropiridin-4-il)fenil)-1,3,4-oksadiazol-2(3H)-ona
(S)-3-metil-5-(4-(1-(2-(6-okso-7-(3-(tetrahidro-2H-piran-4-il)-1H-indazol-5-il)-2,7-diazaspiro[4.4]nonan-2-il)acetil)-1,2,3,6-tetrahidropiridin-4-il)fenil)-1,3,4-oksadiazol-2(3H)-ona
(S)-5-(4-(1-(2-(7-(3-(1-acetilpiperidin-4-il)-1H-indazol-5-il)-6-okso-2,7-diazaspiro[4.4]nonan-2-il)acetil)-1,2,3,6-tetrahidropiridin-4-il)fenil)-3-metil-1,3,4-oksadiazol-2(3H)-ona i
(S)-5-(4-(1-(2-(7-(3-(4-metoksipiperidin-1-il)-1H-indazol-5-il)-6-okso-2,7-diazaspiro[4.4]nonan-2-il)acetil)-1,2,3,6-tetrahidropiridin-4-il)fenil)-3-metil-1,3,4-oksadiazol-2(3H)-ona ili farmaceutski prihvatljive soli bilo čega od navedenog.
10. Spoj u skladu sa zahtjevom 1, odabran iz skupine koja se sastoji od sljedećeg:
[image]
[image]
ili farmaceutski prihvatljive soli bilo čega od navedenog.
11. Spoj koji se odabire iz skupine koja se sastoji od sljedećeg:
[image]
BocN I, BocN CO2H, BocN CONH2, BocN OMe NH i HN N N N ili farmaceutski prihvatljive soli bilo čega od navedenog.
12. Farmaceutski pripravak koji sadrži djelotvornu količinu spoja u skladu s bilo kojim zahtjevom od 1 do 10 ili njegovu farmaceutski prihvatljivu sol te farmaceutski prihvatljivi nosač, sredstvo za razrjeđivanje, ekscipijens ili njihovu kombinaciju.
13. Spoj u skladu s bilo kojim zahtjevom od 1 do 10 ili njegova farmaceutski prihvatljiva sol za uporabu u smanjenju ili liječenju raka, pri čemu se rak odabire iz skupine koja se sastoji od raka pluća, raka gušterače, raka debelog crijeva, mijeloične leukemije, raka štitnjače, mijelodisplastičnog sindroma (MDS), karcinoma mjehura, epidermalnog karcinoma, melanoma, raka dojke, raka prostate, raka glave i vrata, raka jajnika, raka mozga, raka mezenhimalnog podrijetla, sarkoma, tetrakarcinoma, neuroblastoma, karcinoma bubrega, hepatoma, ne-Hodgkinova limfoma, multiplog mijeloma, anaplastičnog karcinoma štitnjače i neurofibromatoze.
14. Spoj u skladu s bilo kojim zahtjevom od 1 do 10 ili njegova farmaceutski prihvatljiva sol za uporabu u sprečavanju replikacije zloćudne novotvorine ili tumora, pri čemu zloćudna novotvorina ili tumor nastaje uslijed raka koji se odabire iz skupine koja se sastoji od raka pluća, raka gušterače, raka debelog crijeva, mijeloične leukemije, raka štitnjače, mijelodisplastičnog sindroma (MDS), karcinoma mjehura, epidermalnog karcinoma, melanoma, raka dojke, raka prostate, raka glave i vrata, raka jajnika, raka mozga, raka mezenhimalnog podrijetla, sarkoma, tetrakarcinoma, neuroblastoma, karcinoma bubrega, hepatoma, ne-Hodgkinova limfoma, multiplog mijeloma, anaplastičnog karcinoma štitnjače i neurofibromatoze.
15. Spoj u skladu s bilo kojim zahtjevom od 1 do 10 ili njegova farmaceutski prihvatljiva sol za uporabu u inhibiciji aktivnosti enzima ERK1 i/ili ERK2 u stanici raka, pri čemu se stanica raka odabire iz skupine koja se sastoji od stanice raka pluća, stanice raka gušterače, stanice raka debelog crijeva, stanice mijeloične leukemije, stanice raka štitnjače, stanice mijelodisplastičnog sindroma (MDS), stanice karcinoma mjehura, stanice epidermalnog karcinoma, stanice melanoma, stanice raka dojke, stanice raka prostate, stanice raka glave i vrata, stanice raka jajnika, stanice raka mozga, stanice raka mezenhimalnog podrijetla, stanice sarkoma, stanice tetrakarcinoma, stanice neuroblastoma, stanice karcinoma bubrega, stanice hepatoma, stanice ne-Hodgkinova limfoma, stanice multiplog mijeloma, stanice anaplastičnog karcinoma štitnjače i stanice neurofibromatoze.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562142946P | 2015-04-03 | 2015-04-03 | |
PCT/US2016/025345 WO2016161160A1 (en) | 2015-04-03 | 2016-03-31 | Spirocyclic compounds |
EP16774232.9A EP3277690B1 (en) | 2015-04-03 | 2016-03-31 | Spirocyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200805T1 true HRP20200805T1 (hr) | 2020-10-16 |
Family
ID=57007413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200805TT HRP20200805T1 (hr) | 2015-04-03 | 2020-05-18 | Spirociklički spojevi |
Country Status (25)
Country | Link |
---|---|
US (3) | US10525036B2 (hr) |
EP (1) | EP3277690B1 (hr) |
JP (1) | JP6737533B2 (hr) |
KR (1) | KR20170132307A (hr) |
CN (1) | CN107849053B (hr) |
AU (1) | AU2016242940B2 (hr) |
BR (1) | BR112017021194A2 (hr) |
CA (1) | CA2981055A1 (hr) |
CY (1) | CY1123019T1 (hr) |
DK (1) | DK3277690T3 (hr) |
ES (1) | ES2788160T3 (hr) |
HK (1) | HK1256671A1 (hr) |
HR (1) | HRP20200805T1 (hr) |
HU (1) | HUE049481T2 (hr) |
IL (1) | IL254662B (hr) |
LT (1) | LT3277690T (hr) |
MX (1) | MX2017012553A (hr) |
PL (1) | PL3277690T3 (hr) |
PT (1) | PT3277690T (hr) |
RS (1) | RS60340B1 (hr) |
RU (1) | RU2745069C2 (hr) |
SG (1) | SG11201707911VA (hr) |
SI (1) | SI3277690T1 (hr) |
TW (1) | TWI705067B (hr) |
WO (1) | WO2016161160A1 (hr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106999451B (zh) * | 2014-09-17 | 2021-04-02 | 里科瑞尔姆Ip控股有限责任公司 | 双环化合物 |
MX2017012553A (es) | 2015-04-03 | 2018-04-11 | Kalyra Pharmaceuticals Inc | Compuestos espirociclicos. |
WO2018067512A1 (en) | 2016-10-05 | 2018-04-12 | Kalyra Pharmaceuticals, Inc. | Spirocyclic compounds |
EP3551610B1 (en) | 2016-12-08 | 2021-08-11 | Board of Regents, The University of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease |
AU2020257301A1 (en) | 2019-04-18 | 2021-11-11 | The Johns Hopkins University | Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof |
US11560366B2 (en) | 2019-10-21 | 2023-01-24 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
CN115124542A (zh) * | 2022-07-08 | 2022-09-30 | 河南师范大学 | 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR057579A1 (es) * | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
US8546404B2 (en) * | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
US7902363B2 (en) | 2006-11-17 | 2011-03-08 | Polyera Corporation | Diimide-based semiconductor materials and methods of preparing and using the same |
US8716483B2 (en) | 2008-02-21 | 2014-05-06 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
WO2010027567A2 (en) | 2008-07-23 | 2010-03-11 | Schering Corporation | Tricyclic spirocycle derivatives and methods of use thereof |
US8658651B2 (en) | 2009-09-30 | 2014-02-25 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
US9687550B2 (en) | 2009-12-07 | 2017-06-27 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
US8664213B2 (en) | 2011-08-29 | 2014-03-04 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as HIV attachment inhibitors |
CN103130775B (zh) * | 2011-11-22 | 2015-09-30 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
US8987264B2 (en) * | 2012-11-09 | 2015-03-24 | Bristol-Myers Squibb Company | 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C |
CA2903431C (en) | 2013-03-14 | 2022-12-06 | Kalyra Pharmaceuticals, Inc. | Bicyclopentane analgesic compounds |
CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
MX2017012553A (es) | 2015-04-03 | 2018-04-11 | Kalyra Pharmaceuticals Inc | Compuestos espirociclicos. |
WO2018067512A1 (en) | 2016-10-05 | 2018-04-12 | Kalyra Pharmaceuticals, Inc. | Spirocyclic compounds |
-
2016
- 2016-03-31 MX MX2017012553A patent/MX2017012553A/es unknown
- 2016-03-31 AU AU2016242940A patent/AU2016242940B2/en not_active Ceased
- 2016-03-31 PT PT167742329T patent/PT3277690T/pt unknown
- 2016-03-31 CN CN201680028591.0A patent/CN107849053B/zh not_active Expired - Fee Related
- 2016-03-31 RU RU2017133973A patent/RU2745069C2/ru active
- 2016-03-31 SG SG11201707911VA patent/SG11201707911VA/en unknown
- 2016-03-31 ES ES16774232T patent/ES2788160T3/es active Active
- 2016-03-31 SI SI201630764T patent/SI3277690T1/sl unknown
- 2016-03-31 HU HUE16774232A patent/HUE049481T2/hu unknown
- 2016-03-31 DK DK16774232.9T patent/DK3277690T3/da active
- 2016-03-31 JP JP2017552060A patent/JP6737533B2/ja not_active Expired - Fee Related
- 2016-03-31 US US15/563,926 patent/US10525036B2/en not_active Expired - Fee Related
- 2016-03-31 KR KR1020177031578A patent/KR20170132307A/ko not_active Application Discontinuation
- 2016-03-31 RS RS20200577A patent/RS60340B1/sr unknown
- 2016-03-31 BR BR112017021194A patent/BR112017021194A2/pt not_active IP Right Cessation
- 2016-03-31 LT LTEP16774232.9T patent/LT3277690T/lt unknown
- 2016-03-31 CA CA2981055A patent/CA2981055A1/en not_active Abandoned
- 2016-03-31 EP EP16774232.9A patent/EP3277690B1/en active Active
- 2016-03-31 PL PL16774232T patent/PL3277690T3/pl unknown
- 2016-03-31 WO PCT/US2016/025345 patent/WO2016161160A1/en active Application Filing
- 2016-04-01 TW TW105110691A patent/TWI705067B/zh not_active IP Right Cessation
-
2017
- 2017-09-25 IL IL254662A patent/IL254662B/en active IP Right Grant
-
2018
- 2018-07-12 HK HK18109066.0A patent/HK1256671A1/zh unknown
-
2019
- 2019-03-15 US US16/354,949 patent/US10493060B2/en not_active Expired - Fee Related
-
2020
- 2020-01-06 US US16/734,857 patent/US20200268714A1/en not_active Abandoned
- 2020-04-10 CY CY20201100356T patent/CY1123019T1/el unknown
- 2020-05-18 HR HRP20200805TT patent/HRP20200805T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200805T1 (hr) | Spirociklički spojevi | |
HRP20210791T1 (hr) | 1-cijano-pirolidin spojevi kao usp30 inhibitori | |
CN107872977B (zh) | Irak4抑制剂与btk抑制剂的组合产品 | |
HRP20180382T1 (hr) | Inhibitori protein kinaze | |
HRP20150185T1 (hr) | Inhibitori kinaza koji reguliraju signalne puteve u apoptozi | |
IL187690A (en) | Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer | |
JP2019513135A5 (hr) | ||
JP2018510183A5 (hr) | ||
RU2015152576A (ru) | Производные индолин-2-она или пирролопиридин/пиримидин-2-она | |
JP2018507861A5 (hr) | ||
AU2017339890A1 (en) | Spirocyclic compounds | |
JP2019504009A5 (hr) | ||
AU2013361127A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
JP2017530960A5 (hr) | ||
HRP20200440T1 (hr) | 1h-pirazolo[4,3-b]piridini kao pde1 inhibitori | |
CA2825699A1 (en) | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | |
CN111417394B (zh) | 苯并咪唑衍生物及其用途 | |
RU2017134379A (ru) | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 | |
US20220296595A1 (en) | Cdk inhibitors | |
JP2018511613A5 (hr) | ||
US20180251431A1 (en) | 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels | |
RU2019116251A (ru) | Пиразоло[3,4-b]пиридины и имидазо[1,5-b]пиридазины в качестве ингибиторов pde1 | |
RU2653500C2 (ru) | Ингибиторы тирозинкиназы брутона | |
US20230382907A1 (en) | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases | |
JPWO2021021986A5 (hr) |